43.78
2.17%
-0.97
アフターアワーズ:
43.78
Ultragenyx Pharmaceutical Inc (RARE) 最新ニュース
State of New Jersey Common Pension Fund D Reduces Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Osteogenesis Imperfecta Treatment Market 2024-2031: Global - openPR
How To Trade (RARE) - Stock Traders Daily
RTW INVESTMENTS, LP Adjusts Stake in Ultragenyx Pharmaceutical I - GuruFocus.com
Ultragenyx Pharmaceutical's SWOT analysis: pipeline progress boosts rare disease stock - Investing.com
Ultragenyx posts trial data backing Phase 3 design for Angelman syndrome therapy - MSN
Ultragenyx Pharmaceutical (NASDAQ:RARE) Receives Buy Rating from Canaccord Genuity Group - MarketBeat
Ultragenyx: Ready For More Growth After Q3 Earnings Beat (NASDAQ:RARE) - Seeking Alpha
Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Research Analysts Offer Predictions for RARE FY2024 Earnings - MarketBeat
Ultragenyx Q3 Loss Narrower Than Expected, Revenues Beat Estimates - MSN
Ultragenyx posts data for Angelman syndrome therapy (RARE:NASDAQ) - Seeking Alpha
Ultragenyx Presents Positive Update on GTX-102 Angelman - GlobeNewswire
Ultragenyx's Angelman Treatment Shows 80% Patient Improvement in Phase 1/2 Trial | RARE Stock News - StockTitan
What is Wedbush's Estimate for RARE FY2024 Earnings? - MarketBeat
Leerink Partnrs Has Negative Outlook of RARE FY2024 Earnings - MarketBeat
What is HC Wainwright's Estimate for RARE FY2024 Earnings? - MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q3 2024 Earnings Call Transcript - Insider Monkey
What is HC Wainwright's Estimate for RARE Q1 Earnings? - MarketBeat
Ultragenyx Pharmaceutical Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St
Ultragenyx Pharmaceutical's (RARE) Overweight Rating Reiterated at Cantor Fitzgerald - MarketBeat
Ultragenyx Pharma stock target raised, retains buy on strong revenue growth - Investing.com India
HC Wainwright Boosts Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $95.00 - MarketBeat
Ultragenyx Pharma stock target raised, retains buy on strong revenue growth By Investing.com - Investing.com South Africa
Evaluating Ultragenyx Pharmaceutical: Insights From 7 Financial Analysts - Benzinga
International Assets Investment Management LLC Boosts Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Ultragenyx: Excellent Company, Lackluster Stock (NASDAQ:RARE) - Seeking Alpha
Ultragenyx Pharmaceutical Inc (RARE) Q3 2024 Earnings Call Highlights: Robust Revenue Growth ... - Yahoo Finance
Ultragenyx Reports Strong Q3 Growth and Milestones - TipRanks
Ultragenyx Pharmaceutical reports an over 40% increase in Q3 revenue - North Bay Business Journal
Ultragenyx Pharmaceutical Q3 2024 Earnings Preview - MSN
Ultragenyx Pharmaceutical Inc (RARE) Q3 2024 Earnings: Revenue S - GuruFocus.com
Ultragenyx (RARE) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Ultragenyx: Q3 Earnings Snapshot - San Francisco Chronicle
Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update - The Manila Times
Ultragenyx Pharmaceutical Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Purchased by Wealth Enhancement Advisory Services LLC - MarketBeat
A Look Ahead: Ultragenyx Pharmaceutical's Earnings Forecast - Benzinga
Trend Tracker for (RARE) - Stock Traders Daily
Emerald Advisers LLC Raises Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
abrdn plc Sells 31,441 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
RAREUltragenyx Pharmaceutical Inc. Latest Stock News & Market Updates - StockTitan
What Makes Ultragenyx Pharmaceutical (RARE) an Exciting Investment Opportunity? - Insider Monkey
Oversold Conditions For Ultragenyx Pharmaceutical (RARE) - Nasdaq
Pinnacle Associates Ltd. Has $6.63 Million Stock Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Ultragenyx Pharmaceutical (RARE) to Release Earnings on Tuesday - MarketBeat
Ultragenyx to Host Conference Call for Third Quarter 2024 Financial Results and Corporate Update - The Manila Times
大文字化:
|
ボリューム (24 時間):